RTP Mobile Logo
Submitted by nenadkesic@gmail.com on Thu, 09/14/2017 - 07:32
ONUL117

Interview with D Ross Camidge, MD, PhD

Track 1: Case discussion: A 56-year-old woman and never smoker with newly diagnosed adenocarcinoma of the lung, a MET exon 14 skipping mutation and a high PD-L1 tumor proportion score (TPS)
Track 2: Changing landscape of clinically relevant predictive biomarkers in advanced non-small cell lung cancer (NSCLC)
Track 3: Efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers
Track 4: Approach to first-line therapy for patients with newly diagnosed adenocarcinoma of the lung, a driver mutation and a high PD-L1 TPS
Track 5: PD-L1 expression level and response to immunotherapy in patients with MET exon 14-altered NSCLC
Track 6: Choosing between pembrolizumab alone or in combination with carboplatin/pemetrexed as first-line therapy for metastatic nonsquamous NSCLC
Track 7: Efficacy and tolerability of crizotinib in MET exon 14-altered NSCLC
Track 8: Results of a Phase II trial of T-DM1 for patients with HER2 mutation-positive NSCLC
Track 9: Investigational strategies for patients with MET-positive NSCLC
Track 10: Treatment after disease progession in patients receiving therapy with an immune checkpoint inhibitor
Track 11: Case discussion: A 62-year-old woman and 60 pack-year smoker who presents with de novo metastatic squamous cell carcinoma (SCC) of the lung and a high PD-L1 TPS experiences a near-complete response with single-agent pembrolizumab
Track 12: Case discussion: A 76-year-old woman and former smoker with SCC, a solitary brain metastasis and a low PD-L1 TPS initially receives carboplatin/paclitaxel
Track 13: Case discussion: A 33-year-old man and never smoker with previously treated adenocarcinoma of the lung is found to harbor an ALK rearrangement
Track 14: Primary results of the Phase III ALEX study: Alectinib versus crizotinib for ALK inhibitor-naïve, ALK-positive metastatic NSCLC
Track 15: Sequencing crizotinib, alectinib, ceritinib and brigatinib
Track 16: Tolerability profiles of FDA-approved ALK inhibitors
Track 17: Case discussion: A 62-year-old man and never smoker with metastatic EGFR L858R mutation-positive adenocarcinoma of the lung
Track 18: EGFR exon 19 deletion mutations and the presence of diffuse miliary nodules
Track 19: Alectinib-associated photosensitivity
Track 20: Case discussion: An 81-year-old woman and former smoker initially diagnosed with pan-wild-type adenocarcinoma of the lung who received carboplatin/pemetrexed is found to harbor a BRAF V600E mutation
Track 21: Activity and tolerability of the antibody-drug conjugate rovalpituzumab tesirine targeting DLL3-expressing tumors in small cell lung cancer (SCLC)

Interview with Heather Wakelee, MD

Track 1: ADJUVANT: Initial results of a Phase III trial evaluating gefitinib versus vinorelbine/cisplatin as adjuvant therapy for Stage II to IIIA NSCLC with EGFR-activating mutations
Track 2: Efficacy of immune checkpoint inhibitors in mesothelioma and SCLC
Track 3: Activity of HER2-targeted agents in patients with HER2-overexpressing advanced NSCLC
Track 4: Sequencing anti-PD-1/PD-L1 antibodies and targeted therapies for patients with NSCLC and driver mutations
Track 5: Pembrolizumab alone or in combination with carboplatin/pemetrexed as first-line therapy for metastatic nonsquamous NSCLC
Track 6: Case discussion: A 33-year-old woman and never smoker with newly diagnosed adenocarcinoma of the lung and a high PD-L1 TPS
Track 7: Case discussion: A 46-year-old woman receives osimertinib after disease progression on erlotinib for EGFR mutation-positive metastatic NSCLC
Track 8: Plasma and urine genotyping to identify T790M mutations in NSCLC
Track 9: Activity of osimertinib in patients with T790M-positive advanced NSCLC and brain metastases
Track 10: Ongoing investigation of osimertinib in earlier lines of therapy
Track 11: Incidence of cardiac toxicity in patients receiving osimertinib
Track 12: Case discussion: A woman in her forties with relapsed/refractory NSCLC is found to harbor a ROS1 translocation
Track 13: Therapeutic options for patients with metastatic NSCLC harboring ROS1 gene rearrangements
Track 14: Clinical experience with immune checkpoint inhibitor-associated pulmonary toxicities
Track 15: ECOG-E1505: A Phase III trial of adjuvant chemotherapy with or without bevacizumab for early-stage NSCLC — A subset analysis of outcomes by chemotherapy
Track 16: Neoadjuvant checkpoint inhibitors for resectable NSCLC
Track 17: Perspective on the activity of rovalpituzumab tesirine in advanced SCLC
Track 18: PACIFIC: A Phase III trial evaluating the anti-PD-L1 antibody durvalumab as monotherapy after chemoradiation therapy for Stage III NSCLC
Track 19: Approach to first-line therapy for patients with metastatic SCC of the lung and low PD-L1 TPS
Track 20: Tolerability of nanoparticle albumin-bound (nab) paclitaxel in advanced SCC of the lung
 
FACULTY:
 
D Ross Camidge, MD, PhD
Professor of Medicine/Oncology
Joyce Zeff Chair in
Lung Cancer Research
University of Colorado
Cancer Center
Aurora, Colorado
 
Heather Wakelee, MD
Professor of Medicine
Division of Oncology
Stanford University School of Medicine
Stanford Cancer Institute
Stanford, California
 
EDITOR:
Neil Love, MD
Research To Practice
Miami, Florida